Resumption of Cochlear Implant Surgery under COVID-19 Pandemic Conditions.
Henryk SkarzynskiArtur LorensBeata DziendzielElzbieta WlodarczykAnita ObryckaAdam WalkowiakPiotr Henryk SkarzynskiPublished in: Life (Basel, Switzerland) (2021)
(1) Background: The novel coronavirus COVID-19 has been recognized by the World Health Organization as a public health emergency of international concern and has caused cancellation of elective cochlear implantation in many countries. This article sets out our experience with resuming cochlear implant (CI) surgery under COVID-19 conditions over a period of 3 months. In addition, early results of hearing preservation (HP) after CI surgery are presented; (2) Methods: We adopted epidemic management policies and procedures according to the National Consultant for Infectious Diseases recommendations. During preoperative visits, all patients were tested for COVID-19 with a RT-PCR test. One month postoperatively, HP values in the Partial Deafness Treatment (PDT) group of patients was established using the HEARRING group formula; (3) Results: Between January and March 2021, we performed 312 CI procedures in adult and pediatric patients. Of these, none were subsequently re-admitted to hospital and found to be COVID-19 positive. Postoperative audiometric results showed that complete or partial HP was achieved in more than half the PDT patients; (4) Conclusion: Cochlear implantation during the coronavirus disease pandemic is essential and, with careful planning, is perfectly feasible.
Keyphrases
- coronavirus disease
- public health
- end stage renal disease
- sars cov
- chronic kidney disease
- ejection fraction
- minimally invasive
- prognostic factors
- newly diagnosed
- patients undergoing
- peritoneal dialysis
- healthcare
- coronary artery bypass
- emergency department
- photodynamic therapy
- infectious diseases
- acute coronary syndrome
- clinical practice
- patient reported outcomes
- smoking cessation
- adverse drug